https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-uveal-melanoma-likelihood-of-approval/ 2025-01-05T16:59:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-05T16:59:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gensci-059-changchun-genescience-pharmaceutical-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T16:59:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diphtheria-pertussis-tetanus-vaccine-chongqing-zhifei-biological-products-diphtheria-likelihood-of-approval/ 2025-01-05T16:59:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T16:59:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-innoup-farma-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-05T16:59:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/drug-for-unspecified-dermatological-disorders-tbt-pharma-unspecified-dermatological-disorders-likelihood-of-approval/ 2025-01-05T16:59:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stem-cell-therapy-2-for-coronavirus-disease-2019-covid-19-celltex-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T16:59:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-butyrate-usp-biokier-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2025-01-05T16:59:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gls-5310-geneone-life-science-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T16:59:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tasipimidine-orion-unspecified-psychiatric-disorders-likelihood-of-approval/ 2025-01-05T16:59:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opzelura-incyte-unspecified-dermatological-disorders-likelihood-of-approval/ 2025-01-05T16:59:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1273-213-moderna-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T16:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-solid-tumor-likelihood-of-approval/ 2025-01-05T16:59:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-05T16:58:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hydrovax-005-najit-technologies-chikungunya-fever-likelihood-of-approval/ 2025-01-05T16:58:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-ovarian-cancer-likelihood-of-approval/ 2025-01-05T16:58:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snb-101-sn-bioscience-head-and-neck-cancer-likelihood-of-approval/ 2025-01-05T16:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/melatonin-repoceuticals-actinic-solar-keratosis-likelihood-of-approval/ 2025-01-05T16:58:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-melanoma-likelihood-of-approval/ 2025-01-05T16:58:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shigella-bivalent-vaccine-chongqing-zhifei-biological-products-bacillary-dysentery-shigellosis-likelihood-of-approval/ 2025-01-05T16:58:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T16:58:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T16:58:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/t-01-treamid-therapeutics-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2025-01-05T16:58:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-001-genome-co-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-05T16:58:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snb-101-sn-bioscience-breast-cancer-likelihood-of-approval/ 2025-01-05T16:58:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-05T16:58:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cp-506-convert-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-05T16:58:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/runimotamab-genentech-usa-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-05T16:58:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ninsipapogene-sibarnarepvec-hookipa-pharma-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-05T16:57:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monoclonal-antibody-to-inhibit-il33-for-autoimmune-disorders-eli-lilly-and-co-autoimmune-disorders-likelihood-of-approval/ 2025-01-05T16:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diphtheria-pertussis-tetanus-vaccine-chongqing-zhifei-biological-products-pertussis-whooping-cough-likelihood-of-approval/ 2025-01-05T16:57:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-05T16:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-colon-cancer-likelihood-of-approval/ 2025-01-05T16:57:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mu-28zt2-wellington-zhaotai-therapies-lung-cancer-likelihood-of-approval/ 2025-01-05T16:57:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dr-10627-zhejiang-doer-biologics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-05T16:57:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rlvt-903-releviate-therapeutics-peripheral-neuropathy-sensory-neuropathy-likelihood-of-approval/ 2025-01-05T16:57:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-4101174-eli-lilly-and-co-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T16:57:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chlorphenesin-carbamate-hydroxychloroquine-oncocross-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T16:57:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tak-186-takeda-pharmaceutical-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-05T16:57:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trientine-hydrochloride-innolife-coronary-artery-disease-cad-ischemic-heart-disease-likelihood-of-approval/ 2025-01-05T16:57:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deuterated-etifoxine-gaba-therapeutics-neuropathic-pain-neuralgia-likelihood-of-approval/ 2025-01-05T16:57:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tas-0728-taiho-pharmaceutical-biliary-tumor-likelihood-of-approval/ 2025-01-05T16:57:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tas-0728-taiho-pharmaceutical-gastric-cancer-likelihood-of-approval/ 2025-01-05T16:56:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yh-013-eucure-beijing-biopharma-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-05T16:56:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/img-004-inmagene-biopharmaceuticals-chronic-urticaria-or-hives-likelihood-of-approval/ 2025-01-05T16:56:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-adizutecan-abbvie-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-05T16:56:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-4101174-eli-lilly-and-co-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T16:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-biosimilar-formycon-melanoma-likelihood-of-approval/ 2025-01-05T16:56:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syncar-001-stk-009-synthekine-lupus-nephritis-likelihood-of-approval/ 2025-01-05T16:56:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snb-101-sn-bioscience-gastric-cancer-likelihood-of-approval/ 2025-01-05T16:56:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biosimilar-dragonboat-biopharmaceutical-shanghai-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-05T16:56:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pep-cmv-immunomic-therapeutics-anaplastic-astrocytoma-likelihood-of-approval/ 2025-01-05T16:56:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-urethral-cancer-likelihood-of-approval/ 2025-01-05T16:56:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-adizutecan-abbvie-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-05T16:56:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hyaluronidase-recombinant-human-pembrolizumab-merck-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T16:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bga-1901-nexbiome-therapeutics-helicobacter-pylori-infections-likelihood-of-approval/ 2025-01-05T16:56:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kls-2031-kolon-life-science-neuropathic-pain-neuralgia-likelihood-of-approval/ 2025-01-05T16:55:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/act-10041239-idorsia-pharmaceutical-multiple-sclerosis-likelihood-of-approval/ 2025-01-05T16:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-3528869a-gsk-hepatitis-b-likelihood-of-approval/ 2025-01-05T16:55:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-471-compass-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2025-01-05T16:55:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimicotinib-hydrochloride-abbisko-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T16:55:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimicotinib-hydrochloride-abbisko-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T16:55:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crs-3123-crestone-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval/ 2025-01-05T16:55:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T16:55:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-malignant-neoplasms-likelihood-of-approval/ 2025-01-05T16:55:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/m-701-wuhan-yzy-biopharma-malignant-pleural-effusion-likelihood-of-approval/ 2025-01-05T16:55:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-mabpharm-chronic-urticaria-or-hives-likelihood-of-approval-2/ 2025-01-05T16:54:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iptacopan-hydrochloride-novartis-myasthenia-gravis-likelihood-of-approval-2/ 2025-01-05T16:53:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/omalizumab-biosimilar-mabpharm-chronic-urticaria-or-hives-likelihood-of-approval/ 2025-01-05T16:53:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iptacopan-hydrochloride-novartis-proteinuria-likelihood-of-approval/ 2025-01-05T16:52:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/iptacopan-hydrochloride-novartis-myasthenia-gravis-likelihood-of-approval/ 2025-01-05T16:52:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/expanding-diagnostic-and-biomarker-options-to-improve-mash-clinical-trials/ 2025-01-03T21:33:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/iitguwahati-bose-institute-hydrogel/ 2025-01-03T13:48:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/davids-goliaths-glp-1r-gold-rush/ 2025-01-03T19:03:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/siga-japan-orthopoxvirus-treatment/ 2025-01-03T10:40:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nmpa-hutchmed-combo-therapy/ 2025-01-03T08:28:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/neumora-shares-sink-following-phase-iii-flop-in-mdd/ 2025-01-02T17:07:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-sotatercept-mhra-approval/ 2025-01-02T14:06:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/tirzepatide-outpace-wegovy-obesity/ 2025-01-02T11:40:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/unmet-need-t2-low-asthma/ 2025-01-02T10:57:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hutchmed-shpl-608m/ 2025-01-02T10:33:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ai-ad-disease-management/ 2025-01-02T10:32:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/innovent-roche-lung-cancer-therapy/ 2025-01-07T09:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sangamos-stock-sinks-50-as-pfizer-halts-haemophilia-a-gene-therapy-partnership/ 2025-01-08T10:30:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tebapivat-agios-pharmaceuticals-sickle-cell-disease-likelihood-of-approval/ 2025-01-05T16:52:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lxe-408-novartis-chagas-disease-american-trypanosomiasis-likelihood-of-approval/ 2024-12-31T05:59:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xaluritamig-amgen-prostate-cancer-likelihood-of-approval/ 2024-12-31T05:59:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvp-1805r2-nvp-healthcare-unspecified-cardiovascular-disorders-likelihood-of-approval/ 2024-12-31T05:59:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2024-12-31T05:59:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-gallbladder-cancer-likelihood-of-approval/ 2024-12-31T05:59:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iptacopan-hydrochloride-novartis-granulomatosis-with-polyangiitis-wegener-s-granulomatosis-likelihood-of-approval/ 2024-12-31T05:59:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-7439-carrick-therapeutics-breast-cancer-likelihood-of-approval/ 2024-12-31T05:59:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itm-91-itm-isotope-technologies-munich-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-31T05:59:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itm-91-itm-isotope-technologies-munich-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-31T05:58:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itm-91-itm-isotope-technologies-munich-solid-tumor-likelihood-of-approval/ 2024-12-31T05:58:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ineo-vac-p01-hangzhou-neoantigen-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-31T05:58:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vutiglabridin-glaceum-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-31T05:58:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ckd-510-novartis-charcot-marie-tooth-disease-likelihood-of-approval/ 2024-12-31T05:58:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bitr-2101-boston-immune-technologies-and-therapeutics-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-31T05:58:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stk-012-synthekine-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-31T05:58:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stk-012-synthekine-colorectal-cancer-likelihood-of-approval/ 2024-12-31T05:58:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcd-245-biocad-ewing-sarcoma-likelihood-of-approval/ 2024-12-31T05:58:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3789-prelude-therapeutics-colorectal-cancer-likelihood-of-approval/ 2024-12-31T05:58:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imc-2015-immunecyte-osteonecrosis-likelihood-of-approval/ 2024-12-31T05:58:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifaximin-nexpharm-korea-irritable-bowel-syndrome-likelihood-of-approval/ 2024-12-31T05:58:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlodipine-indapamide-valsartan-ahn-gook-pharmaceutical-idiopathic-essential-hypertension-likelihood-of-approval/ 2024-12-31T05:58:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aba-101-abata-therapeutics-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2024-12-31T05:58:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-1-maxinovel-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-31T05:57:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pts-500-gongwin-biopharm-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T05:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-157-aveta-biomics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-31T05:57:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tas-0728-taiho-pharmaceutical-endometrial-cancer-likelihood-of-approval/ 2024-12-31T05:57:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/laromestrocel-longeveron-hypoplastic-left-heart-syndrome-likelihood-of-approval/ 2024-12-31T05:57:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selenium-sulfide-azura-ophthalmics-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2024-12-31T05:57:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mor-210-biogen-autoimmune-disorders-likelihood-of-approval/ 2024-12-31T05:57:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-000262-incyte-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-31T05:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linavonkibart-scholar-rock-nasopharyngeal-cancer-likelihood-of-approval/ 2024-12-31T05:57:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linavonkibart-scholar-rock-uterine-cancer-likelihood-of-approval/ 2024-12-31T05:57:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xb-010-exelixis-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-31T05:57:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rd-1301-nanjing-bioheng-biotech-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-31T05:57:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fbr-002-fab-entech-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T05:57:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pociredir-fulcrum-therapeutics-sickle-cell-disease-likelihood-of-approval/ 2024-12-31T05:56:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimicotinib-hydrochloride-abbisko-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-31T05:56:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immedica-to-buy-marinus/ 2024-12-31T05:46:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimicotinib-hydrochloride-abbisko-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T03:57:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1117568-neurocrine-biosciences-schizophrenia-likelihood-of-approval/ 2024-12-31T03:56:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmpl-306-hutchison-medipharma-myeloproliferative-disorders-likelihood-of-approval/ 2024-12-31T03:56:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-melanoma-likelihood-of-approval/ 2024-12-31T03:56:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-ovarian-cancer-likelihood-of-approval/ 2024-12-31T03:56:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csb-001-claris-biotherapeutics-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2024-12-31T03:56:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esk-001-alumis-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2024-12-31T03:56:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bendamustine-hydrochloride-mecox-cure-med-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-31T03:56:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-47d11-abbvie-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balcinrenone-dapagliflozin-astrazeneca-proteinuria-likelihood-of-approval/ 2024-12-31T03:56:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dc-853-dice-therapeutics-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2024-12-31T03:56:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-amniotic-epithelial-stem-cells-icell-biotechnology-parkinson-s-disease-likelihood-of-approval/ 2024-12-31T03:56:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hy-133-hypharm-staphylococcal-infections-likelihood-of-approval/ 2024-12-31T03:56:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cirtuvivint-biosplice-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-31T03:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-12-31T03:56:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plixorafenib-fore-biotherapeutics-low-grade-glioma-likelihood-of-approval/ 2024-12-31T03:55:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6631-f-hoffmann-la-roche-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-31T03:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linavonkibart-scholar-rock-liver-cancer-likelihood-of-approval/ 2024-12-31T03:55:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sbp-101-spark-biopharma-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-31T03:55:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/norketotifen-emergo-therapeutics-chronic-fatigue-syndrome-myalgic-encephalomyelitis-likelihood-of-approval/ 2024-12-31T03:55:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmpl-760-hutchison-medipharma-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-31T03:55:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-19155-lg-chem-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-31T03:55:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebtelovimab-eli-lilly-and-co-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:55:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autogene-cevumeran-genentech-usa-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2024-12-31T03:55:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oxfendazole-oxfendazole-development-group-neurocysticercosis-likelihood-of-approval/ 2024-12-31T03:55:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-immunodeficiency-virus-vaccine-aelix-therapeutics-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-12-31T03:55:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pts-500-gongwin-biopharm-malignant-pleural-effusion-likelihood-of-approval/ 2024-12-31T03:55:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-31T03:55:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pts-100-gongwin-biopharm-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-31T03:54:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dnth-103-dianthus-therapeutics-multifocal-motor-neuropathy-likelihood-of-approval/ 2024-12-31T03:54:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulecaciclib-aucentra-therapeutics-liver-cancer-likelihood-of-approval/ 2024-12-31T03:54:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-endometrial-cancer-likelihood-of-approval/ 2024-12-31T03:54:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bioven-biopharma-plasma-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-31T03:54:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-101-antengene-colorectal-cancer-likelihood-of-approval/ 2024-12-31T03:54:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamiparib-beigene-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-31T03:54:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-jazz-pharmaceuticals-rett-syndrome-likelihood-of-approval/ 2024-12-31T03:54:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acloproxalap-aldeyra-therapeutics-coronavirus-disease-2019-covid-19-associated-cytokine-release-syndrome-likelihood-of-approval/ 2024-12-31T03:54:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caficrestat-applied-therapeutics-diabetic-peripheral-neuropathy-likelihood-of-approval/ 2024-12-31T03:54:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-31T03:54:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1283-moderna-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:54:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-1184-genmab-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-31T03:54:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rbd-5044-suzhou-ribo-life-sciences-familial-chylomicronemia-type-i-hyperlipoproteinemia-likelihood-of-approval/ 2024-12-31T03:54:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-ritonavir-modra-pharmaceuticals-bladder-cancer-likelihood-of-approval/ 2024-12-31T03:53:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tozorakimab-astrazeneca-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:53:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulscs-restem-gastrointestinal-bleeding-gastrointestinal-hemorrhage-likelihood-of-approval/ 2024-12-31T03:53:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07054894-pfizer-ulcerative-colitis-likelihood-of-approval/ 2024-12-31T03:53:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ub-612-vaxxinity-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:53:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alm-412-almirall-epidermolysis-bullosa-likelihood-of-approval/ 2024-12-31T03:53:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caficrestat-applied-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aum-001-aum-biosciences-solid-tumor-likelihood-of-approval/ 2024-12-31T03:53:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-1184-genmab-peritoneal-cancer-likelihood-of-approval/ 2024-12-31T03:53:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/covid-19-s-protein-vaxart-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:53:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bmb-101-bright-minds-biosciences-absence-seizure-likelihood-of-approval/ 2024-12-31T03:53:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-covid-19-vaccine-2-sinopharm-group-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:53:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cholecalciferol-risedronate-sodium-dongkook-pharmaceutical-post-menopausal-osteoporosis-likelihood-of-approval/ 2024-12-31T03:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blb-101-blue-lake-biotechnology-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:53:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tas-0728-taiho-pharmaceutical-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-31T03:52:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tas-0728-taiho-pharmaceutical-solid-tumor-likelihood-of-approval/ 2024-12-31T03:52:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baluretgene-parvec-ocugen-leber-congenital-amaurosis-lca-likelihood-of-approval/ 2024-12-31T03:52:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dactolisib-tosylate-adicet-bio-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:52:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eedvd-682-engeneic-melanoma-likelihood-of-approval/ 2024-12-31T03:52:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-31T03:52:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen1e-1124-gen1e-lifesciences-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-31T03:52:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lomvastomig-f-hoffmann-la-roche-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T03:52:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/morf-057-eli-lilly-and-co-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-31T03:52:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kd-4003-kyung-dong-diabetes-likelihood-of-approval/ 2024-12-31T03:52:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prtx-007-primmune-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T03:52:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-8002-biotheus-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-31T03:52:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-leiomyosarcoma-likelihood-of-approval/ 2024-12-31T03:52:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baluretgene-parvec-ocugen-retinitis-pigmentosa-retinitis-likelihood-of-approval/ 2024-12-31T03:52:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iptacopan-hydrochloride-novartis-microscopic-polyangiitis-mpa-likelihood-of-approval/ 2024-12-31T03:51:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nirmatrelvir-ritonavir-pfizer-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-31T03:51:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-ananda-scientific-pain-likelihood-of-approval/ 2024-12-31T03:51:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-003-drug-farm-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2024-12-31T03:51:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-silo-pharma-parkinson-s-disease-likelihood-of-approval/ 2024-12-31T03:51:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-319-itabmed-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-31T03:51:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ruxoprubart-novelmed-therapeutics-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2024-12-31T03:51:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctil-051-abelzeta-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T03:51:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-2-replimune-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-31T03:51:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-2-replimune-salivary-gland-cancer-likelihood-of-approval/ 2024-12-31T03:51:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-2-replimune-gastric-cancer-likelihood-of-approval/ 2024-12-31T03:51:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-esophageal-cancer-likelihood-of-approval/ 2024-12-31T03:51:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-uterine-cancer-likelihood-of-approval/ 2024-12-31T03:51:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-breast-cancer-likelihood-of-approval/ 2024-12-31T03:51:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tas-1440-taiho-pharmaceutical-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-31T03:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iptacopan-hydrochloride-novartis-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2024-12-31T03:50:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hy-133-hypharm-methicillin-susceptible-staphylococcus-aureus-mssa-infections-likelihood-of-approval/ 2024-12-31T03:50:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtp-500-barinthus-biotherapeutics-middle-east-respiratory-syndrome-mers-likelihood-of-approval/ 2024-12-31T03:50:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-and-cd22-targeted-car-t-therapy-chongqing-precision-biotech-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-31T03:50:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-and-cd22-targeted-car-t-therapy-chongqing-precision-biotech-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-31T03:50:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalnicastobart-lyvgen-biopharma-head-and-neck-carcinoma-likelihood-of-approval/ 2024-12-31T03:50:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-2113-johnson-johnson-psoriatic-arthritis-likelihood-of-approval/ 2024-12-31T03:50:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cytisinicline-achieve-life-sciences-smoking-cessation-likelihood-of-approval/ 2024-12-31T03:50:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eculizumab-biosimilar-isu-abxis-autoimmune-disorders-likelihood-of-approval/ 2024-12-31T03:50:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acetylcysteine-zidrimer-orpheris-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-31T03:50:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-31T03:50:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-cervical-cancer-likelihood-of-approval/ 2024-12-31T03:50:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tev-56192-teva-pharmaceutical-industries-unspecified-neurologic-disorders-likelihood-of-approval/ 2024-12-31T03:50:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-19-shanghai-yake-biotechnology-follicular-lymphoma-likelihood-of-approval/ 2024-12-31T03:49:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-inflammatory-aimmax-therapeutics-inflammation-likelihood-of-approval/ 2024-12-31T03:49:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-inflammatory-aimmax-therapeutics-post-operative-pain-likelihood-of-approval/ 2024-12-31T03:49:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/beroterkib-taiho-pharmaceutical-melanoma-likelihood-of-approval/ 2024-12-31T03:49:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-868-nuvation-bio-ovarian-cancer-likelihood-of-approval/ 2024-12-31T03:49:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prime-msk-shot-thomas-advanced-medical-unspecified-neurologic-disorders-likelihood-of-approval/ 2024-12-31T03:49:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ins-08055-insilico-medicine-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-12-31T03:49:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inflammatory-bowel-disease-torrent-pharmaceuticals-inflammatory-bowel-disease-likelihood-of-approval/ 2024-12-31T03:49:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-vipivotide-tetraxetan-advanced-accelerator-applications-neuroendocrine-cancer-likelihood-of-approval/ 2024-12-31T03:49:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tumorad-spago-nanomedical-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-31T03:49:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilurgisertib-fumarate-incyte-myelofibrosis-likelihood-of-approval/ 2024-12-31T03:49:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilurgisertib-fumarate-incyte-anemia-likelihood-of-approval/ 2024-12-31T03:49:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilurgisertib-fumarate-incyte-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-31T03:49:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986419-bristol-myers-squibb-alzheimer-s-disease-likelihood-of-approval/ 2024-12-31T03:49:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamtocabtagene-autoleucel-miltenyi-biomedicine-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-31T03:48:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/satricabtagene-autoleucel-carsgen-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-12-31T03:48:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-vulvar-cancer-likelihood-of-approval/ 2024-12-31T03:48:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-anal-cancer-likelihood-of-approval/ 2024-12-31T03:48:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-solid-tumor-likelihood-of-approval/ 2024-12-31T03:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T03:47:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syncar-001-stk-009-synthekine-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-31T03:46:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ql-401-qlsf-biotherapeutics-solid-tumor-likelihood-of-approval/ 2024-12-31T02:49:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ql-401-qlsf-biotherapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-31T02:49:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astrostem-v-nature-cell-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-31T02:49:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-19-imunopharm-technology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-31T02:48:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-ritonavir-modra-pharmaceuticals-esophageal-cancer-likelihood-of-approval/ 2024-12-31T02:48:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-ritonavir-modra-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:48:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-ritonavir-modra-pharmaceuticals-head-and-neck-cancer-likelihood-of-approval/ 2024-12-31T02:48:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-jazz-pharmaceuticals-schizophrenia-likelihood-of-approval/ 2024-12-31T02:48:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyrotinib-jiangsu-hengrui-medicine-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-31T02:48:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-pancreatic-cancer-likelihood-of-approval/ 2024-12-31T02:48:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-31T02:48:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-metastatic-melanoma-likelihood-of-approval/ 2024-12-31T02:48:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balcinrenone-dapagliflozin-astrazeneca-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2024-12-31T02:48:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-covid-19-vaccine-hdt-bio-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T02:48:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/larotrectinib-sulfate-bayer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:48:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fs-118-f-star-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:48:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bifikafusp-alfa-onfekafusp-alfa-philogen-kaposi-sarcoma-likelihood-of-approval/ 2024-12-31T02:47:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-12-31T02:47:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-765049-boehringer-ingelheim-international-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-31T02:47:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sra-515-gsk-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-31T02:47:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zectivimod-lg-chem-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-31T02:47:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eedvd-682-engeneic-head-and-neck-cancer-likelihood-of-approval/ 2024-12-31T02:47:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-colorectal-cancer-likelihood-of-approval/ 2024-12-31T02:47:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-3-maxinovel-pharmaceuticals-alopecia-areata-likelihood-of-approval/ 2024-12-31T02:47:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gavorestat-applied-therapeutics-unspecified-metabolic-disorders-likelihood-of-approval/ 2024-12-31T02:47:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-831-biomed-industries-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T02:47:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bitr-2101-boston-immune-technologies-and-therapeutics-t-cell-leukemia-likelihood-of-approval/ 2024-12-31T02:47:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bitr-2101-boston-immune-technologies-and-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-31T02:47:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-19-shanghai-yake-biotechnology-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-31T02:47:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wp-1303-worg-pharmaceuticals-hangzhou-posterior-uveitis-likelihood-of-approval/ 2024-12-31T02:47:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sx-682-syntrix-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:46:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sx-682-syntrix-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-31T02:46:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-2100-biohaven-neuropathic-pain-neuralgia-likelihood-of-approval/ 2024-12-31T02:46:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptx-9908-pertinax-therapeutics-liver-cancer-likelihood-of-approval/ 2024-12-31T02:46:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-19155-lg-chem-metastatic-melanoma-likelihood-of-approval/ 2024-12-31T02:46:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oxime-methoxime-bodor-laboratories-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2024-12-31T02:46:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tele-bodor-laboratories-unspecified-dermatological-disorders-likelihood-of-approval/ 2024-12-31T02:46:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hlc-001-human-life-cord-japan-unspecified-respiratory-disorders-likelihood-of-approval/ 2024-12-31T02:46:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apr-002-apros-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T02:46:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-primary-cns-lymphoma-likelihood-of-approval/ 2024-12-31T02:46:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-64315-les-laboratoires-servier-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-31T02:46:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-64315-les-laboratoires-servier-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-31T02:46:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-6194-merck-vitiligo-likelihood-of-approval/ 2024-12-31T02:46:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aav-htert-libella-gene-therapeutics-ageing-likelihood-of-approval/ 2024-12-31T02:46:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gumarontinib-shanghai-haihe-biopharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:45:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/androgenetic-alopecia-cosmo-pharmaceuticals-androgenic-alopecia-likelihood-of-approval/ 2024-12-31T02:45:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovleplenib-acetate-hutchison-medipharma-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-31T02:45:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovleplenib-acetate-hutchison-medipharma-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-31T02:45:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/citarinostat-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-31T02:45:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bifikafusp-alfa-onfekafusp-alfa-philogen-metastatic-melanoma-likelihood-of-approval/ 2024-12-31T02:45:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-31T02:45:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cll1-cd33-ccar-t-cells-icell-gene-therapeutics-myeloproliferative-disorders-likelihood-of-approval/ 2024-12-31T02:45:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctim-76-context-therapeutics-testicular-cancer-likelihood-of-approval/ 2024-12-31T02:45:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elzovantinib-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:45:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/melatonin-repoceuticals-gastrointestinal-radiation-toxicity-likelihood-of-approval/ 2024-12-31T02:45:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omo-103-peptomyc-osteosarcoma-likelihood-of-approval/ 2024-12-31T02:45:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sco-267-scohia-pharma-obesity-likelihood-of-approval/ 2024-12-31T02:45:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blb-01d1-bristol-myers-squibb-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-31T02:44:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sh-748-nanjing-sanhome-pharmaceutical-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-31T02:44:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvk-004-nevakar-injectables-unspecified-cardiovascular-disorders-likelihood-of-approval/ 2024-12-31T02:44:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gl-7190-gliknik-autoimmune-disorders-likelihood-of-approval/ 2024-12-31T02:44:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zasocitinib-takeda-pharmaceutical-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-31T02:44:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imatinib-aerami-therapeutics-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2024-12-31T02:44:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apr-003-apros-therapeutics-hepatitis-b-likelihood-of-approval/ 2024-12-31T02:44:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-metastatic-prostate-cancer-likelihood-of-approval/ 2024-12-31T02:44:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xoglo-kimera-labs-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-31T02:44:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obrixtamig-boehringer-ingelheim-international-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-12-31T02:44:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obrixtamig-boehringer-ingelheim-international-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:44:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vidofludimus-calcium-immunic-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-31T02:44:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blb-01d1-bristol-myers-squibb-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-31T02:44:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bafisontamab-epimab-biotherapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-31T02:43:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/satricabtagene-autoleucel-carsgen-therapeutics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-12-31T02:43:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-3068-jacobio-pharmaceuticals-group-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-31T02:43:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-3068-jacobio-pharmaceuticals-group-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-31T02:43:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/4d-310-4d-molecular-therapeutics-fabry-disease-likelihood-of-approval/ 2024-12-31T02:43:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ki-3106-kuhnil-pharmaceutical-hyperlipidemia-likelihood-of-approval/ 2024-12-31T02:43:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amitriptyline-hydrochloride-algotherapeutix-diabetic-peripheral-neuropathy-likelihood-of-approval/ 2024-12-31T02:43:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-31T02:43:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulscs-restem-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-31T02:43:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/slynd-insud-pharma-endometriosis-likelihood-of-approval/ 2024-12-31T02:43:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crovalimab-f-hoffmann-la-roche-atypical-hemolytic-uremic-syndrome-nondiarrhea-associated-hemolytic-uremic-syndrome-likelihood-of-approval/ 2024-12-31T02:43:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inpegsomatropin-xiamen-amoytop-biotech-born-small-for-gestational-age-sga-likelihood-of-approval/ 2024-12-31T02:43:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-31T02:43:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iron-sucrose-stannic-protoporfin-renibus-therapeutics-acute-renal-failure-arf-acute-kidney-injury-likelihood-of-approval/ 2024-12-31T02:43:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orelabrutinib-innocare-pharma-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-31T02:42:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/in-m00001-hk-inno-n-reflux-esophagitis-gastroesophageal-reflux-disease-likelihood-of-approval/ 2024-12-31T02:42:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rbd-5044-suzhou-ribo-life-sciences-hypertriglyceridemia-likelihood-of-approval/ 2024-12-31T02:42:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kit-2014-kither-biotech-cystic-fibrosis-likelihood-of-approval/ 2024-12-31T02:42:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dactolisib-tosylate-everolimus-adicet-bio-respiratory-tract-infections-likelihood-of-approval/ 2024-12-31T02:42:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-breast-cancer-likelihood-of-approval/ 2024-12-31T02:42:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snb-101-sn-bioscience-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:42:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vebreltinib-dr-apollomics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-31T02:42:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-metastatic-melanoma-likelihood-of-approval/ 2024-12-31T02:42:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doxecitine-doxribtimine-ucb-inherited-mitochondrial-disorders-likelihood-of-approval/ 2024-12-31T02:42:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sn-117m-dota-annexin-v-serene-atherosclerosis-likelihood-of-approval/ 2024-12-31T02:42:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abl-103-aurum-biosciences-inflammation-likelihood-of-approval/ 2024-12-31T02:42:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-19-imunopharm-technology-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-31T02:42:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oms-1029-omeros-unspecified-immunological-disorders-likelihood-of-approval/ 2024-12-31T02:41:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spl-026-cybin-major-depressive-disorder-likelihood-of-approval/ 2024-12-31T02:41:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imiquimod-zalifrelimab-urogen-pharma-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2024-12-31T02:41:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-001-agastiya-biotech-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-31T02:41:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abiraterone-austhera-biosciences-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2024-12-31T02:41:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eedvd-682-engeneic-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-12-31T02:41:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-edodekin-alfa-cytix-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-31T02:41:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snb-101-sn-bioscience-colorectal-cancer-likelihood-of-approval/ 2024-12-31T02:41:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qrl-101-quralis-epilepsy-likelihood-of-approval/ 2024-12-31T02:40:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-cd22-car-t-shanghai-unicar-therapy-bio-medicine-technology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-31T02:40:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mtx-covab-memo-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval-2/ 2024-12-31T02:39:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mtx-covab-memo-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-31T02:39:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6540-f-hoffmann-la-roche-follicular-lymphoma-likelihood-of-approval/ 2024-12-31T02:38:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdr-404-cdr-life-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T19:38:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vidofludimus-calcium-immunic-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:38:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vicadrostat-boehringer-ingelheim-international-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-30T19:38:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-124-icell-gene-therapeutics-t-cell-acute-lymphocytic-leukemia-t-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-30T19:38:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-neuroendocrine-tumors-likelihood-of-approval/ 2024-12-30T19:38:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-lymphoma-likelihood-of-approval/ 2024-12-30T19:38:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navocaftor-sionna-therapeutics-cystic-fibrosis-likelihood-of-approval/ 2024-12-30T19:38:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mv-130-inmunotek-lower-respiratory-tract-infections-likelihood-of-approval/ 2024-12-30T19:38:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-kaposi-sarcoma-likelihood-of-approval/ 2024-12-30T19:37:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/q-901-qurient-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T19:37:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2024-12-30T19:37:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nafamostat-mesylate-ensysce-biosciences-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:37:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mymd-1-tnf-pharmaceuticals-hashimoto-thyroiditis-likelihood-of-approval/ 2024-12-30T19:37:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemafibrate-tofogliflozin-kowa-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-30T19:37:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gma-106-gmax-biopharm-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-30T19:37:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gma-106-gmax-biopharm-type-2-diabetes-likelihood-of-approval/ 2024-12-30T19:37:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cp-506-convert-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T19:37:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cp-506-convert-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:37:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mesenchymal-stromal-cell-therapy-orbsen-therapeutics-autoimmune-hepatitis-likelihood-of-approval/ 2024-12-30T19:37:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:37:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axatilimab-incyte-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T19:37:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onc-206-chimerix-high-grade-glioma-likelihood-of-approval/ 2024-12-30T19:36:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regdanvimab-celltrion-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:36:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:36:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gct-103-s-quatre-cerebral-palsy-likelihood-of-approval/ 2024-12-30T19:36:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-177lu-zadavotide-guraxetan-eli-lilly-and-co-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T19:36:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/idor-1134-2831-idorsia-pharmaceutical-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval/ 2024-12-30T19:36:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/certepetide-lisata-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T19:36:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-06835919-pfizer-unspecified-metabolic-disorders-likelihood-of-approval/ 2024-12-30T19:36:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T19:36:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alintegimod-7-hills-pharma-solid-tumor-likelihood-of-approval/ 2024-12-30T19:36:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alrizomadlin-ascentage-pharma-group-international-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T19:36:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-laryngeal-cancer-likelihood-of-approval/ 2024-12-30T19:36:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-endometrial-cancer-likelihood-of-approval/ 2024-12-30T19:36:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tev-56192-teva-pharmaceutical-industries-unspecified-immunological-disorders-likelihood-of-approval/ 2024-12-30T19:35:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alec-04-alentis-therapeutics-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-30T19:35:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/novaferon-genova-biotech-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:35:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zigakibart-novartis-iga-nephropathy-berger-s-disease-likelihood-of-approval/ 2024-12-30T19:35:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danazol-viramal-endometriosis-likelihood-of-approval/ 2024-12-30T19:35:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-gastrointestinal-tumor-likelihood-of-approval/ 2024-12-30T19:35:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-rectal-cancer-likelihood-of-approval/ 2024-12-30T19:35:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deuterated-etifoxine-gaba-therapeutics-post-partum-depression-maternal-depression-postnatal-depression-likelihood-of-approval/ 2024-12-30T19:35:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-4-maxinovel-pharmaceuticals-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T19:35:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-4-maxinovel-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-30T19:35:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-4-maxinovel-pharmaceuticals-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T19:35:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2024-12-30T19:35:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plasmodium-immunotherapy-cas-lamvac-biotech-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:34:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ta-1505-merck-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T19:34:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alec-04-alentis-therapeutics-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:34:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T19:34:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zolacabtagene-autoleucel-bristol-myers-squibb-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T19:34:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/samuraciclib-carrick-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:34:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-metastatic-prostate-cancer-likelihood-of-approval/ 2024-12-30T19:34:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/giroctocogene-fitelparvovec-pfizer-hemophilia-a-factor-viii-deficiency-likelihood-of-approval/ 2024-12-30T19:34:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-lispro-u100-adocia-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-12-30T19:34:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cm-24-purple-biotech-melanoma-likelihood-of-approval/ 2024-12-30T19:34:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cm-24-purple-biotech-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:34:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-30T19:34:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tnb-738-ancora-biotech-unspecified-immunological-disorders-likelihood-of-approval/ 2024-12-30T19:34:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emp-012-empirico-unspecified-immunological-disorders-likelihood-of-approval/ 2024-12-30T19:33:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gxp-1-egret-therapeutics-transplant-rejection-likelihood-of-approval/ 2024-12-30T19:33:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tas-0728-taiho-pharmaceutical-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:33:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-6194-merck-ulcerative-colitis-likelihood-of-approval/ 2024-12-30T19:33:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/raludotatug-deruxtecan-daiichi-sankyo-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T19:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/garetosmab-regeneron-pharmaceuticals-fibrodysplasia-ossificans-progressiva-myositis-ossificans-progressiva-likelihood-of-approval/ 2024-12-30T19:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plasmodium-immunotherapy-cas-lamvac-biotech-liver-cancer-likelihood-of-approval/ 2024-12-30T19:33:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naltrexone-hydrochloride-statera-biopharma-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:33:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calpurbatug-trellis-bioscience-methicillin-resistant-staphylococcus-aureus-mrsa-infections-likelihood-of-approval/ 2024-12-30T19:33:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pr-15-advancecor-coronary-artery-disease-cad-ischemic-heart-disease-likelihood-of-approval/ 2024-12-30T19:33:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-201-brl-medicine-mantle-cell-lymphoma-likelihood-of-approval-2/ 2024-12-30T19:33:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clmht-01-closed-loop-medicine-hypertension-likelihood-of-approval/ 2024-12-30T19:33:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-101-brl-medicine-sickle-cell-disease-likelihood-of-approval/ 2024-12-30T19:33:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/117-lu-dgul-cellbion-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T19:32:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:32:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T19:32:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/raludotatug-deruxtecan-daiichi-sankyo-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T19:32:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/absk-043-abbisko-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:32:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sh-748-nanjing-sanhome-pharmaceutical-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-30T19:32:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gal-475-neurim-pharmaceuticals-sleep-apnea-likelihood-of-approval/ 2024-12-30T19:32:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-7214-rhizen-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:32:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alx-1-vast-therapeutics-bronchiectasis-likelihood-of-approval/ 2024-12-30T19:32:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tuspetinib-aptose-biosciences-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-12-30T19:32:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xb-2203-xbiotech-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval/ 2024-12-30T19:32:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbm-588-miyarisan-pharmaceutical-lung-cancer-likelihood-of-approval/ 2024-12-30T19:32:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/indenebart-astrazeneca-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/ 2024-12-30T19:32:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-malignant-fibrous-histiocytoma-likelihood-of-approval/ 2024-12-30T19:31:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polihexanide-sifi-parasitic-acanthamoeba-corneal-ulcers-likelihood-of-approval/ 2024-12-30T19:31:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cy-101-cytovation-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T19:31:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imvotamab-igm-biosciences-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/ 2024-12-30T19:31:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-endometrial-cancer-likelihood-of-approval/ 2024-12-30T19:31:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hx-009-waterstone-hanxbio-malignant-mesothelioma-likelihood-of-approval/ 2024-12-30T19:31:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hx-009-waterstone-hanxbio-esophageal-cancer-likelihood-of-approval/ 2024-12-30T19:31:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xyf-19-xi-an-yufan-biotechnology-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T19:31:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zw-171-zymeworks-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:31:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zw-171-zymeworks-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:31:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T19:31:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cy-101-cytovation-liver-cancer-likelihood-of-approval/ 2024-12-30T19:31:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ef-001-everfront-biotech-high-grade-glioma-likelihood-of-approval/ 2024-12-30T19:31:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azercabtagene-zapreleucel-imugene-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-30T19:30:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xyf-19-xi-an-yufan-biotechnology-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-30T19:30:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vir-5818-vir-biotechnology-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-30T19:30:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirabegron-tamsulosin-hydrochloride-dongkoo-bio-pharma-benign-prostatic-hyperplasia-likelihood-of-approval/ 2024-12-30T19:30:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pucotenlimab-lepu-biopharma-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2024-12-30T19:30:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inv-102-invirsa-diabetic-macular-edema-likelihood-of-approval/ 2024-12-30T19:30:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npg-2044-novita-pharmaceuticals-thyroid-cancer-likelihood-of-approval/ 2024-12-30T19:30:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T19:30:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/energif-703-energenesis-biomedical-diabetic-foot-ulcers-likelihood-of-approval/ 2024-12-30T19:30:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cftx-1554-eli-lilly-and-co-peripheral-neuropathic-pain-likelihood-of-approval/ 2024-12-30T19:30:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kba-1412-kling-biotherapeutics-melanoma-likelihood-of-approval/ 2024-12-30T19:30:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agen-2373-agenus-adrenal-gland-cancer-likelihood-of-approval/ 2024-12-30T19:30:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levacetylleucine-intrabio-spinocerebellar-ataxia-sca-likelihood-of-approval/ 2024-12-30T19:30:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:29:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:29:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-gastrointestinal-tract-cancer-likelihood-of-approval/ 2024-12-30T19:29:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/t-1101-taivex-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T19:29:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levacetylleucine-intrabio-ataxia-telangiectasia-louis-bar-syndrome-likelihood-of-approval/ 2024-12-30T19:29:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sra-515-gsk-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T19:29:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-023-les-laboratoires-servier-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:29:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2223-chia-tai-tianqing-pharmaceutical-group-solid-tumor-likelihood-of-approval/ 2024-12-30T19:29:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brimarafenib-mapkure-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:29:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgba-445-beigene-advanced-malignancy-likelihood-of-approval/ 2024-12-30T19:29:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onvapegleukin-alfa-ascendis-pharma-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2024-12-30T19:29:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sage-319-sage-therapeutics-unspecified-central-nervous-system-disorders-likelihood-of-approval/ 2024-12-30T19:29:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-metastatic-lung-cancer-likelihood-of-approval/ 2024-12-30T19:29:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cnty-101-century-therapeutics-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-30T19:28:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fcn-338-fochon-pharmaceutical-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T19:28:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sra-515-gsk-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:28:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abiraterone-austhera-biosciences-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2024-12-30T19:28:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mipletamig-aptevo-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T19:28:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:28:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocx-063-occurx-diabetic-retinopathy-likelihood-of-approval/ 2024-12-30T19:28:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gersizangitide-asclepix-therapeutics-choroidal-neovascularization-likelihood-of-approval/ 2024-12-30T19:28:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalpiciclib-jiangsu-hengrui-medicine-breast-cancer-likelihood-of-approval/ 2024-12-30T19:28:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/miricorilant-corcept-therapeutics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-30T19:28:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gersizangitide-asclepix-therapeutics-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-12-30T19:28:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-gastrointestinal-tract-cancer-likelihood-of-approval/ 2024-12-30T19:27:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lt-5001-ltt-bio-pharma-unspecified-neurologic-disorders-likelihood-of-approval/ 2024-12-30T19:27:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-thymoma-thymic-epithelial-tumor-likelihood-of-approval/ 2024-12-30T19:25:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpg-1860-hepagene-therapeutics-shanghai-inflammatory-bowel-disease-likelihood-of-approval/ 2024-12-30T19:25:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aic-100-affyimmune-therapeutics-anaplastic-thyroid-cancer-likelihood-of-approval/ 2024-12-30T19:25:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mib-626-metro-international-biotech-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:25:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltanexor-karyopharm-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T19:25:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lucicebtide-sapience-therapeutics-sarcomas-likelihood-of-approval/ 2024-12-30T19:25:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-30T19:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linrodostat-mesylate-bristol-myers-squibb-advanced-malignancy-likelihood-of-approval/ 2024-12-30T19:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-103-genemedicine-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T19:25:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-1402-eureka-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T19:25:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-lupus-nephritis-likelihood-of-approval/ 2024-12-30T19:25:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hx-009-waterstone-hanxbio-head-and-neck-cancer-likelihood-of-approval/ 2024-12-30T19:25:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-small-intestine-cancer-likelihood-of-approval/ 2024-12-30T19:25:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelenectide-pevedotin-bicycle-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T19:25:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-gastric-cancer-likelihood-of-approval/ 2024-12-30T19:25:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T19:25:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fuzuloparib-jiangsu-hengrui-medicine-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T19:24:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/soquelitinib-corvus-pharmaceuticals-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-12-30T19:24:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gxv-001-gexval-angelman-syndrome-likelihood-of-approval/ 2024-12-30T19:24:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-7201-evopoint-bioscience-solid-tumor-likelihood-of-approval/ 2024-12-30T19:24:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/som-1311-som-biotech-phenylketonuria-pku-likelihood-of-approval/ 2024-12-30T19:24:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grwd-5769-grey-wolf-therapeutics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-12-30T19:24:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/darovasertib-ideaya-biosciences-uveal-melanoma-likelihood-of-approval/ 2024-12-30T19:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grn-300-greenfire-bio-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-30T19:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eedvd-682-engeneic-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:24:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/soquelitinib-corvus-pharmaceuticals-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T19:24:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-12-30T19:24:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eedvd-682-engeneic-bladder-cancer-likelihood-of-approval/ 2024-12-30T19:24:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-colon-cancer-likelihood-of-approval/ 2024-12-30T19:24:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-rectal-cancer-likelihood-of-approval/ 2024-12-30T19:24:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-2-replimune-nasopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:23:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ec-313-evestra-unspecified-gynecological-disorders-likelihood-of-approval/ 2024-12-30T19:23:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ap-472-appello-pharmaceuticals-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T19:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-papillomavirus-9-valent-vaccine-xiamen-innovax-biotech-human-papillomavirus-infections-likelihood-of-approval/ 2024-12-30T19:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icalcaprant-cerevel-therapeutics-bipolar-i-disorder-likelihood-of-approval/ 2024-12-30T19:23:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sbp-101-spark-biopharma-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T19:23:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ln-145-iovance-biotherapeutics-ewing-sarcoma-likelihood-of-approval/ 2024-12-30T19:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acetaminophen-hydrocodone-bitartrate-ir-acura-pharmaceuticals-pain-likelihood-of-approval/ 2024-12-30T19:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cnty-101-century-therapeutics-lupus-nephritis-likelihood-of-approval/ 2024-12-30T19:23:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-vulvar-cancer-likelihood-of-approval/ 2024-12-30T19:23:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T19:23:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kl4-surfactant-windtree-therapeutics-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T19:23:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-2-replimune-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-30T19:23:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-lymphoma-likelihood-of-approval/ 2024-12-30T19:23:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retlirafusp-alfa-jiangsu-hengrui-medicine-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:23:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zavegepant-hydrochloride-pfizer-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:23:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csl-889-csl-sickle-cell-disease-likelihood-of-approval/ 2024-12-30T19:22:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-217-phanes-therapeutics-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-12-30T19:22:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cotadutide-astrazeneca-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-30T19:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-solid-tumor-likelihood-of-approval/ 2024-12-30T19:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:22:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icerguastat-inflectis-bioscience-charcot-marie-tooth-disease-type-i-b-likelihood-of-approval/ 2024-12-30T19:22:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astx-295-taiho-pharmaceutical-well-differentiated-liposarcoma-likelihood-of-approval/ 2024-12-30T19:22:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:22:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-108-mustang-bio-recurrent-malignant-glioma-likelihood-of-approval/ 2024-12-30T19:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-gallbladder-cancer-likelihood-of-approval/ 2024-12-30T19:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bimatoprost-laboratoires-thea-ocular-hypertension-likelihood-of-approval/ 2024-12-30T19:22:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lerapolturev-istari-oncology-high-grade-glioma-likelihood-of-approval/ 2024-12-30T19:22:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monlunabant-inversago-pharma-diabetic-nephropathy-likelihood-of-approval/ 2024-12-30T19:22:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifxhu-20-tuhura-biosciences-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-12-30T19:22:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ena-001-enalare-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:21:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T19:21:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T19:21:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cerebrolysin-ever-neuro-pharma-unspecified-neurologic-disorders-likelihood-of-approval/ 2024-12-30T19:21:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/h-3b6545-eisai-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T19:21:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-laryngeal-cancer-likelihood-of-approval/ 2024-12-30T19:21:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afamitresgene-autoleucel-adaptimmune-therapeutics-round-cell-liposarcoma-likelihood-of-approval/ 2024-12-30T19:21:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plasmodium-immunotherapy-cas-lamvac-biotech-brain-tumor-likelihood-of-approval/ 2024-12-30T19:21:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-chia-tai-tianqing-pharmaceutical-group-cervical-cancer-likelihood-of-approval/ 2024-12-30T19:21:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ponsegromab-pfizer-cancer-anorexia-cachexia-syndrome-likelihood-of-approval/ 2024-12-30T19:21:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nxp-800-nuvectis-pharma-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:21:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nxp-800-nuvectis-pharma-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T19:21:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meplazumab-jiangsu-pacific-meinuoke-bio-pharmarceutical-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-30T19:21:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbl-007-beigene-advanced-malignancy-likelihood-of-approval/ 2024-12-30T19:21:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T19:20:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-218-bayer-solid-tumor-likelihood-of-approval/ 2024-12-30T19:20:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cy-101-cytovation-solid-tumor-likelihood-of-approval/ 2024-12-30T19:20:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-12-30T19:20:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abl-103-abl-bio-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T19:20:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-64315-les-laboratoires-servier-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T19:20:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gensci-059-changchun-genescience-pharmaceutical-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T19:20:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acetylcysteine-zidrimer-orpheris-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T19:20:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctim-76-context-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:20:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cll1-cd33-ccar-t-cells-icell-gene-therapeutics-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T19:20:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:20:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clesrovimab-merck-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-12-30T19:20:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azercabtagene-zapreleucel-imugene-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-30T19:20:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:20:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/beroterkib-taiho-pharmaceutical-solid-tumor-likelihood-of-approval/ 2024-12-30T19:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azercabtagene-zapreleucel-imugene-mantle-cell-lymphoma-likelihood-of-approval-2/ 2024-12-30T19:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bifikafusp-alfa-onfekafusp-alfa-philogen-keratoacanthoma-likelihood-of-approval/ 2024-12-30T19:19:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snb-101-sn-bioscience-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:19:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/long-acting-injectable-program-intra-cellular-therapies-schizoaffective-disorder-likelihood-of-approval/ 2024-12-30T19:19:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bifikafusp-alfa-onfekafusp-alfa-philogen-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-12-30T19:19:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/goflikicept-r-pharm-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T19:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rencofilstat-hepion-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mp-1032-metriopharm-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:19:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fasudil-woolsey-pharmaceuticals-progressive-supranuclear-palsy-likelihood-of-approval/ 2024-12-30T19:19:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snb-101-sn-bioscience-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T19:19:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isunakinra-buzzard-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T19:19:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-solid-tumor-likelihood-of-approval/ 2024-12-30T19:18:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biosimilar-dragonboat-biopharmaceutical-shanghai-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-30T19:18:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-765049-boehringer-ingelheim-international-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T19:18:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T19:18:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hiv-1-vaccine-auro-vaccines-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-12-30T19:18:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutikizumab-abbvie-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-30T19:18:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iopofosine-i-131-cellectar-biosciences-ependymoma-likelihood-of-approval/ 2024-12-30T19:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pts-500-gongwin-biopharm-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:18:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adg-106-adagene-suzhou-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:18:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T19:18:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dtcp-vaccine-beijing-minhai-biotechnology-tetanus-likelihood-of-approval/ 2024-12-30T19:18:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalpiciclib-jiangsu-hengrui-medicine-endometrial-cancer-likelihood-of-approval/ 2024-12-30T19:18:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mazindol-er-nls-pharmaceutics-narcolepsy-likelihood-of-approval/ 2024-12-30T19:18:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vebreltinib-dr-apollomics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T19:17:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-765049-boehringer-ingelheim-international-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T19:17:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fm-101-future-medicine-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2024-12-30T19:17:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-2-replimune-esophageal-cancer-likelihood-of-approval/ 2024-12-30T19:17:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deuterated-etifoxine-gaba-therapeutics-social-anxiety-disorder-sad-social-phobia-likelihood-of-approval/ 2024-12-30T19:17:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quabodepistat-otsuka-pharmaceutical-pulmonary-tuberculosis-likelihood-of-approval/ 2024-12-30T19:17:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-4-maxinovel-pharmaceuticals-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T19:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-4-maxinovel-pharmaceuticals-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T19:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ec-5026-eicosis-osteoarthritis-pain-likelihood-of-approval/ 2024-12-30T19:17:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T19:17:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-gastric-cancer-likelihood-of-approval/ 2024-12-30T19:17:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etrumadenant-arcus-biosciences-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:17:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mil-62-beijing-mabworks-biotech-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval-2/ 2024-12-30T19:17:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jns-101-jupiter-neurosciences-friedreich-ataxia-likelihood-of-approval/ 2024-12-30T19:17:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/descartes-15-cartesian-therapeutics-autoimmune-disorders-likelihood-of-approval/ 2024-12-30T19:17:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aav-htert-libella-gene-therapeutics-critical-limb-ischemia-likelihood-of-approval/ 2024-12-30T19:17:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vbi-1901-vbi-vaccines-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T19:16:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retifanlimab-incyte-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:16:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aumolertinib-mesylate-jiangsu-hansoh-pharmaceutical-group-lung-adenocarcinoma-likelihood-of-approval/ 2024-12-30T19:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/in-115314-hk-inno-n-rheumatoid-arthritis-likelihood-of-approval/ 2024-12-30T19:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bifikafusp-alfa-onfekafusp-alfa-philogen-merkel-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:16:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-19018-lg-chem-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-30T19:16:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-sodium-takeda-pharmaceutical-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-30T19:16:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iloperidone-lai-vanda-pharmaceuticals-schizophrenia-likelihood-of-approval/ 2024-12-30T19:16:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lucicebtide-sapience-therapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T19:16:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amt-162-uniqure-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-30T19:16:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltanexor-karyopharm-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pbf-1650-palo-biofarma-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-30T19:16:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etentamig-abbvie-primary-systemic-amyloidosis-likelihood-of-approval/ 2024-12-30T19:16:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decitabine-tetrahydrouridine-novo-nordisk-beta-thalassaemia-likelihood-of-approval/ 2024-12-30T19:15:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sugemalimab-cstone-pharmaceuticals-t-cell-lymphomas-likelihood-of-approval/ 2024-12-30T19:15:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iptacopan-hydrochloride-novartis-glomerulonephritis-likelihood-of-approval/ 2024-12-30T19:15:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-liposarcoma-likelihood-of-approval/ 2024-12-30T19:15:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donepezil-hydrochloride-memantine-hydrochloride-hyundai-pharma-senile-dementia-likelihood-of-approval/ 2024-12-30T19:15:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hy-133-hypharm-methicillin-resistant-staphylococcus-aureus-mrsa-infections-likelihood-of-approval/ 2024-12-30T19:15:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/samuraciclib-carrick-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:15:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-30T19:15:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-b-cell-chronic-lymphocytic-leukemia-likelihood-of-approval/ 2024-12-30T19:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vebreltinib-dr-apollomics-head-and-neck-cancer-likelihood-of-approval/ 2024-12-30T19:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/proagio-proda-biotech-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T19:15:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peg-irinotecan-jenkem-technology-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:15:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sildenafil-citrate-odf-avenir-wellness-solutions-erectile-dysfunction-likelihood-of-approval/ 2024-12-30T19:15:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpv-16-e7-gilead-sciences-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:15:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revumenib-citrate-syndax-pharmaceuticals-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:15:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sco-240-scohia-pharma-cholelithiasis-likelihood-of-approval/ 2024-12-30T19:15:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zw-171-zymeworks-malignant-mesothelioma-likelihood-of-approval/ 2024-12-30T19:14:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-metastatic-uveal-melanoma-likelihood-of-approval/ 2024-12-30T19:14:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-head-and-neck-cancer-likelihood-of-approval/ 2024-12-30T19:14:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-12-30T19:14:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-30T19:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-4830-merck-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-30T19:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cirtuvivint-biosplice-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T19:14:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amesanar-rheacell-diabetic-foot-ulcers-likelihood-of-approval/ 2024-12-30T19:14:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peceleganan-jiangsu-protelight-pharmaceutical-biotechnology-diabetic-foot-ulcers-likelihood-of-approval/ 2024-12-30T19:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-cart-19-1-miltenyi-biomedicine-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-30T19:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-nasopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:14:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:14:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-endometrial-cancer-likelihood-of-approval/ 2024-12-30T19:14:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:14:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trospium-chloride-xanomeline-tartrate-bristol-myers-squibb-schizophrenia-likelihood-of-approval/ 2024-12-30T19:13:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:13:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-bladder-cancer-likelihood-of-approval/ 2024-12-30T19:13:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropivacaine-er-painreform-post-operative-pain-likelihood-of-approval/ 2024-12-30T19:13:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enpatoran-merck-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T19:13:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/il2-cd25-bristol-myers-squibb-autoimmune-disorders-likelihood-of-approval/ 2024-12-30T19:13:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axatilimab-incyte-solid-tumor-likelihood-of-approval/ 2024-12-30T19:13:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-30T19:13:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fp-045-foresee-pharmaceuticals-pulmonary-arterial-hypertension-likelihood-of-approval/ 2024-12-30T19:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epinephrine-aquestive-therapeutics-anaphylaxis-likelihood-of-approval/ 2024-12-30T19:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opevesostat-merck-metastatic-prostate-cancer-likelihood-of-approval/ 2024-12-30T19:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T19:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/humanized-cd19-car-t-cells-shanghai-unicar-therapy-bio-medicine-technology-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-12-30T19:12:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-mantle-cell-lymphoma-likelihood-of-approval-2/ 2024-12-30T19:12:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2024-12-30T19:12:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enasidenib-mesylate-bristol-myers-squibb-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-12-30T19:12:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2024-12-30T19:12:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-30T19:12:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-21-imunopharm-technology-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T19:12:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rulonilimab-shandong-new-time-pharmaceutical-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T19:12:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monepantel-neurizon-therapeutics-motor-neuron-diseases-likelihood-of-approval/ 2024-12-30T19:12:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-037-antengene-hematological-tumor-likelihood-of-approval/ 2024-12-30T19:12:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anxv-annexin-pharmaceuticals-retinal-vein-occlusion-likelihood-of-approval/ 2024-12-30T19:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-219-purple-biotech-breast-cancer-likelihood-of-approval/ 2024-12-30T19:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lis-1-xenothera-natural-killer-cell-lymphomas-likelihood-of-approval/ 2024-12-30T19:12:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986419-bristol-myers-squibb-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-30T19:12:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2024-12-30T19:11:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ion-859-ionis-pharmaceuticals-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T19:11:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adpa-2afp-adaptimmune-therapeutics-lung-cancer-likelihood-of-approval/ 2024-12-30T19:11:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adpa-2afp-adaptimmune-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T19:11:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bitr-2101-boston-immune-technologies-and-therapeutics-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-12-30T19:11:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sunobinop-tosylate-imbrium-therapeutics-alcohol-dependence-likelihood-of-approval/ 2024-12-30T19:11:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anavex-371-anavex-life-sciences-frontotemporal-dementia-ftd-likelihood-of-approval/ 2024-12-30T19:11:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-12-30T19:11:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bisantrene-race-oncology-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T19:11:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gd2-cart01-bellicum-pharmaceuticals-medulloblastoma-likelihood-of-approval/ 2024-12-30T19:11:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stemchymal-steminent-biotherapeutics-spinocerebellar-ataxia-sca-likelihood-of-approval/ 2024-12-30T19:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T19:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sco-267-scohia-pharma-diabetes-likelihood-of-approval/ 2024-12-30T19:11:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/es-4000-escend-pharmaceuticals-melanoma-likelihood-of-approval/ 2024-12-30T19:11:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/survodutide-boehringer-ingelheim-international-overweight-likelihood-of-approval/ 2024-12-30T19:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stp-938-step-pharma-solid-tumor-likelihood-of-approval/ 2024-12-30T19:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-relatlimab-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:10:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pradusinstobart-lyvgen-biopharma-solid-tumor-likelihood-of-approval/ 2024-12-30T19:10:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cll1-cd33-ccar-t-cells-icell-gene-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T19:10:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-19-shanghai-yake-biotechnology-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T19:10:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-androgen-sensitive-prostate-cancer-likelihood-of-approval/ 2024-12-30T19:10:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bars-13-beijing-advaccine-biotechnology-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-12-30T19:10:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/can-3110-candel-therapeutics-anaplastic-astrocytoma-likelihood-of-approval/ 2024-12-30T19:10:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T19:10:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kba-1412-kling-biotherapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T19:10:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ict-01-imcheck-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T19:10:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icerguastat-inflectis-bioscience-charcot-marie-tooth-disease-type-i-a-likelihood-of-approval/ 2024-12-30T19:10:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/h-1337-d-western-therapeutics-institute-open-angle-glaucoma-likelihood-of-approval/ 2024-12-30T19:10:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctim-76-context-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-12-30T19:10:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-urethral-cancer-likelihood-of-approval/ 2024-12-30T19:10:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ksi-501-kodiak-sciences-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-12-30T19:09:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anp-390-alphanavi-pharma-peripheral-neuropathic-pain-likelihood-of-approval/ 2024-12-30T19:09:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nalbuphine-hydrochloride-er-trevi-therapeutics-prurigo-likelihood-of-approval/ 2024-12-30T19:09:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diphtheria-pertussis-tetanus-vaccine-chongqing-zhifei-biological-products-tetanus-likelihood-of-approval/ 2024-12-30T19:09:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lgk-974-novartis-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T19:09:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avadomide-hydrochloride-bristol-myers-squibb-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T19:09:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sra-515-gsk-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T19:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levacetylleucine-intrabio-tay-sachs-disease-likelihood-of-approval/ 2024-12-30T19:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-adenoid-cystic-carcinoma-acc-likelihood-of-approval/ 2024-12-30T19:09:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-liver-cancer-likelihood-of-approval/ 2024-12-30T19:09:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T19:09:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanubrutinib-beigene-lupus-nephritis-likelihood-of-approval/ 2024-12-30T19:09:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-gastric-cancer-likelihood-of-approval/ 2024-12-30T19:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bebt-260-guangzhou-bebetter-medicine-technology-penile-cancer-likelihood-of-approval/ 2024-12-30T19:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-30T19:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/curcumin-glucuronide-therabiopharma-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/risperidone-er-lyndra-therapeutics-schizophrenia-likelihood-of-approval/ 2024-12-30T19:08:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:08:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eedvd-682-engeneic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:08:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-001-alexion-pharmaceuticals-methylmalonic-acidemia-likelihood-of-approval/ 2024-12-30T19:08:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plixorafenib-fore-biotherapeutics-central-nervous-system-cns-tumor-likelihood-of-approval/ 2024-12-30T19:08:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-12-30T19:08:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pxl-770-poxel-adrenoleukodystrophy-x-linked-adrenoleukodystrophy-x-ald-likelihood-of-approval/ 2024-12-30T19:08:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T19:08:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-anal-cancer-likelihood-of-approval/ 2024-12-30T19:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/av-001-vasomune-therapeutics-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T19:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:08:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-burkitt-lymphoma-likelihood-of-approval/ 2024-12-30T19:08:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/varegacestat-immunome-t-cell-acute-lymphocytic-leukemia-t-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-30T19:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T19:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lv-305-merck-synovial-sarcoma-likelihood-of-approval/ 2024-12-30T19:07:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fs-118-f-star-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T19:07:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cp-506-convert-pharmaceuticals-head-and-neck-cancer-likelihood-of-approval/ 2024-12-30T19:07:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-210c-axoltis-pharma-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-30T19:07:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-5-maxinovel-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-30T19:07:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cp-506-convert-pharmaceuticals-prostate-cancer-likelihood-of-approval/ 2024-12-30T19:07:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acetylcysteine-zidrimer-orpheris-adrenoleukodystrophy-x-linked-adrenoleukodystrophy-x-ald-likelihood-of-approval/ 2024-12-30T19:07:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daplusiran-tomligisiran-gsk-hepatitis-d-likelihood-of-approval/ 2024-12-30T19:07:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-30T19:07:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rovunaptabin-berlin-cures-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-30T19:07:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danicopan-alexion-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:07:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acud-1-accuitis-rosacea-likelihood-of-approval/ 2024-12-30T19:07:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tigilanol-tiglate-qbiotics-group-breast-cancer-likelihood-of-approval/ 2024-12-30T19:07:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tigilanol-tiglate-qbiotics-group-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:07:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bifikafusp-alfa-onfekafusp-alfa-philogen-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-12-30T19:06:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erc-1671-erc-belgium-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T19:06:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brigimadlin-boehringer-ingelheim-international-solid-tumor-likelihood-of-approval/ 2024-12-30T19:06:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bifikafusp-alfa-onfekafusp-alfa-philogen-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2024-12-30T19:06:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nexi-001-neximmune-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T19:06:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/runimotamab-genentech-usa-gastric-cancer-likelihood-of-approval/ 2024-12-30T19:06:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-r-pharm-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asc-60-sagimet-biosciences-solid-tumor-likelihood-of-approval/ 2024-12-30T19:06:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovleplenib-acetate-hutchison-medipharma-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-30T19:06:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-765049-boehringer-ingelheim-international-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T19:06:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nb-004-newbay-medical-technology-solid-tumor-likelihood-of-approval/ 2024-12-30T19:06:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lae-005-laekna-solid-tumor-likelihood-of-approval/ 2024-12-30T19:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-765049-boehringer-ingelheim-international-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mil-62-beijing-mabworks-biotech-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-30T19:06:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-831-biomed-industries-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T19:06:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifaquizinone-tennor-therapeutics-irritable-bowel-syndrome-likelihood-of-approval/ 2024-12-30T19:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stk-002-stoke-therapeutics-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2024-12-30T19:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezabenlimab-boehringer-ingelheim-international-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T19:05:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-219-purple-biotech-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:05:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenalisib-rhizen-pharmaceuticals-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T19:05:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezabenlimab-boehringer-ingelheim-international-solid-tumor-likelihood-of-approval/ 2024-12-30T19:05:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltanexor-karyopharm-therapeutics-adenocarcinoma-likelihood-of-approval/ 2024-12-30T19:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-zynerba-pharmaceuticals-partial-seizure-likelihood-of-approval/ 2024-12-30T19:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repotrectinib-bristol-myers-squibb-thyroid-cancer-likelihood-of-approval/ 2024-12-30T19:05:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exg-34217-elixirgen-therapeutics-bone-disorders-likelihood-of-approval/ 2024-12-30T19:05:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ub-941-ubi-pharma-solid-tumor-likelihood-of-approval/ 2024-12-30T19:05:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-103-cellestia-biotech-adenoid-cystic-carcinoma-acc-likelihood-of-approval/ 2024-12-30T19:05:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inpegsomatropin-xiamen-amoytop-biotech-turner-syndrome-likelihood-of-approval/ 2024-12-30T19:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ziltivekimab-novo-nordisk-myocardial-infarction-likelihood-of-approval/ 2024-12-30T19:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-endometrial-cancer-likelihood-of-approval/ 2024-12-30T19:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inpegsomatropin-xiamen-amoytop-biotech-idiopathic-short-stature-likelihood-of-approval/ 2024-12-30T19:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ketorolac-tromethamine-neumentum-post-operative-pain-likelihood-of-approval/ 2024-12-30T19:04:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inm-004-inmunova-typical-hemolytic-uremic-syndrome-shiga-toxin-associated-hemolytic-uremic-syndrome-likelihood-of-approval/ 2024-12-30T19:04:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quemliclustat-arcus-biosciences-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T19:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meloxicam-rizatriptan-axsome-therapeutics-migraine-likelihood-of-approval/ 2024-12-30T19:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ln-145-iovance-biotherapeutics-primary-cns-lymphoma-likelihood-of-approval/ 2024-12-30T19:04:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repotrectinib-bristol-myers-squibb-salivary-gland-cancer-likelihood-of-approval/ 2024-12-30T19:04:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-lung-cancer-likelihood-of-approval/ 2024-12-30T19:04:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:04:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-cervical-cancer-likelihood-of-approval/ 2024-12-30T19:04:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telacebec-qurient-buruli-ulcer-likelihood-of-approval/ 2024-12-30T19:04:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-7439-carrick-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T19:04:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:04:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-tanvex-biopharma-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T19:04:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cirtuvivint-biosplice-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T19:04:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plasmodium-immunotherapy-cas-lamvac-biotech-thyroid-cancer-likelihood-of-approval/ 2024-12-30T19:03:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:03:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tuspetinib-aptose-biosciences-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T19:03:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plasmodium-immunotherapy-cas-lamvac-biotech-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:03:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dordaviprone-hydrochloride-chimerix-prostate-cancer-likelihood-of-approval/ 2024-12-30T19:03:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:03:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afamitresgene-autoleucel-adaptimmune-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-12-30T19:03:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afamitresgene-autoleucel-adaptimmune-therapeutics-myxoid-liposarcoma-likelihood-of-approval/ 2024-12-30T19:03:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvrgx-314-abbvie-diabetic-macular-edema-likelihood-of-approval/ 2024-12-30T19:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ficerafusp-alfa-bicara-therapeutics-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T19:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-dedifferentiated-liposarcoma-likelihood-of-approval/ 2024-12-30T19:03:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-598-alopexx-unspecified-infectious-diseases-likelihood-of-approval/ 2024-12-30T19:03:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ustekinumab-biosimilar-bio-thera-solutions-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2024-12-30T19:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-30T19:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npg-2044-novita-pharmaceuticals-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-30T19:02:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lis-1-xenothera-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-12-30T19:02:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixadesiran-pixofisiran-sirnaomics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T19:02:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixadesiran-pixofisiran-sirnaomics-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-12-30T19:02:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vactosertib-medpacto-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:02:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vactosertib-medpacto-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T19:02:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niu-440-novartis-lung-adenocarcinoma-likelihood-of-approval/ 2024-12-30T19:02:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T19:02:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ersodetug-rezolute-hyperinsulinemia-likelihood-of-approval/ 2024-12-30T19:02:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/testosterone-viramal-female-hypoactive-sexual-desire-disorder-likelihood-of-approval/ 2024-12-30T19:02:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T19:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-nivolumab-bristol-myers-squibb-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vactosertib-medpacto-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-30T19:02:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-gliosarcoma-likelihood-of-approval/ 2024-12-30T19:02:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/t-1101-taivex-therapeutics-advanced-malignancy-likelihood-of-approval/ 2024-12-30T19:01:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teriparatide-entera-bio-hypoparathyroidism-likelihood-of-approval/ 2024-12-30T19:01:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blb-01d1-bristol-myers-squibb-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-12-30T19:01:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sco-267-scohia-pharma-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-30T19:01:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalpiciclib-jiangsu-hengrui-medicine-dedifferentiated-liposarcoma-likelihood-of-approval/ 2024-12-30T19:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ziltivekimab-novo-nordisk-anemia-likelihood-of-approval/ 2024-12-30T19:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/progesterone-glia-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-12-30T19:01:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/organ-dysfunction-mortality-bioaegis-therapeutics-sepsis-likelihood-of-approval/ 2024-12-30T19:01:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azercabtagene-zapreleucel-imugene-follicular-lymphoma-likelihood-of-approval-2/ 2024-12-30T19:01:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cy-101-cytovation-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T19:01:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/samcyprone-phio-pharmaceuticals-alopecia-areata-likelihood-of-approval/ 2024-12-30T19:01:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brimarafenib-mapkure-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T19:01:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sng-1153-shenogen-pharma-group-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T19:01:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/frevecitinib-kinaset-therapeutics-asthma-likelihood-of-approval/ 2024-12-30T19:01:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6101-innate-pharma-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T19:00:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dpxe-7-biovaxys-technology-cervical-cancer-likelihood-of-approval/ 2024-12-30T19:00:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrc-01-inovio-pharmaceuticals-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-12-30T19:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rslv-132-resolve-therapeutics-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-30T19:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cy-101-cytovation-lymphoma-likelihood-of-approval/ 2024-12-30T19:00:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golidocitinib-dizal-pharmaceutical-unspecified-immunological-disorders-likelihood-of-approval/ 2024-12-30T19:00:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xzb-0004-signalchem-lifesciences-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T19:00:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zw-171-zymeworks-solid-tumor-likelihood-of-approval/ 2024-12-30T19:00:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T19:00:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utidelone-biostar-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2024-12-30T19:00:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sra-515-gsk-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T19:00:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-ritonavir-modra-pharmaceuticals-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T19:00:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surzebiclimab-beigene-advanced-malignancy-likelihood-of-approval/ 2024-12-30T19:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brimarafenib-mapkure-solid-tumor-likelihood-of-approval/ 2024-12-30T19:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-breast-cancer-likelihood-of-approval/ 2024-12-30T19:00:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tapotoclax-amgen-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T19:00:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tapotoclax-amgen-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:59:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azelaprag-bioage-labs-obesity-likelihood-of-approval/ 2024-12-30T18:59:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:59:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-nasopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T18:59:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olx-07010-oligomerix-mild-cognitive-impairment-likelihood-of-approval/ 2024-12-30T18:59:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-hydrochloride-innopharmax-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:59:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ciltacabtagene-autoleucel-legend-biotech-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-12-30T18:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cm-24-purple-biotech-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-esophageal-cancer-likelihood-of-approval/ 2024-12-30T18:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:59:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-lispro-pramlintide-adocia-obesity-likelihood-of-approval/ 2024-12-30T18:59:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T18:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/semzuvolimab-united-biopharma-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-12-30T18:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:58:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T18:58:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/petosemtamab-merus-laryngeal-cancer-likelihood-of-approval/ 2024-12-30T18:58:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tapotoclax-amgen-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:58:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lucicebtide-sapience-therapeutics-gastrointestinal-tract-cancer-likelihood-of-approval/ 2024-12-30T18:58:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dronabinol-palmidrol-evero-health-tourette-syndrome-likelihood-of-approval/ 2024-12-30T18:58:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omt-28-omeicos-therapeutics-mitochondrial-myopathy-likelihood-of-approval/ 2024-12-30T18:58:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elezanumab-abbvie-acute-ischemic-stroke-likelihood-of-approval/ 2024-12-30T18:58:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-idiopathic-cd4-lymphocytopenia-likelihood-of-approval/ 2024-12-30T18:58:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:58:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belrestotug-gsk-solid-tumor-likelihood-of-approval/ 2024-12-30T18:58:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lpmx-2-lipomedix-pharmaceutical-bladder-cancer-likelihood-of-approval/ 2024-12-30T18:58:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-gastric-cancer-likelihood-of-approval/ 2024-12-30T18:58:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltanexor-karyopharm-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:58:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plixorafenib-fore-biotherapeutics-anaplastic-oligoastrocytoma-likelihood-of-approval/ 2024-12-30T18:57:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repotrectinib-bristol-myers-squibb-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:57:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sefaxersen-sodium-f-hoffmann-la-roche-iga-nephropathy-berger-s-disease-likelihood-of-approval/ 2024-12-30T18:57:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shigetec-eveliqure-biotechnologies-bacillary-dysentery-shigellosis-likelihood-of-approval/ 2024-12-30T18:57:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rejuveinix-reven-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T18:57:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omt-28-omeicos-therapeutics-cardiomyopathy-likelihood-of-approval/ 2024-12-30T18:57:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-human-recombinant-elgan-pharma-malabsorption-syndrome-likelihood-of-approval/ 2024-12-30T18:57:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rejuveinix-reven-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T18:57:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltanexor-karyopharm-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:57:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T18:57:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cart22-cart22-65s-cells-novartis-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-30T18:57:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltanexor-karyopharm-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:57:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/akp-11-akaal-pharma-autoimmune-disorders-likelihood-of-approval/ 2024-12-30T18:57:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-jazz-pharmaceuticals-developmental-disorders-likelihood-of-approval/ 2024-12-30T18:57:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etbx-051-etbx-061-etbx-011-immunitybio-hereditary-nonpolyposis-colon-cancer-likelihood-of-approval/ 2024-12-30T18:57:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retifanlimab-incyte-endometrial-cancer-likelihood-of-approval/ 2024-12-30T18:57:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosmanogepix-basilea-pharmaceutica-unspecified-fungal-infections-likelihood-of-approval/ 2024-12-30T18:56:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-12-30T18:56:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/ 2024-12-30T18:56:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cr-9114-leyden-laboratories-influenzavirus-a-infections-likelihood-of-approval/ 2024-12-30T18:56:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T18:56:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ruvembri-biophytis-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T18:56:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/larotrectinib-sulfate-bayer-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:56:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-esophageal-cancer-likelihood-of-approval/ 2024-12-30T18:56:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-cervical-cancer-likelihood-of-approval/ 2024-12-30T18:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diacc-3010-evexta-bio-lymphoma-likelihood-of-approval/ 2024-12-30T18:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-solid-tumor-likelihood-of-approval/ 2024-12-30T18:56:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apx-3330-opus-genetics-non-proliferative-diabetic-retinopathy-npdr-likelihood-of-approval/ 2024-12-30T18:56:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:56:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-gastric-cancer-likelihood-of-approval/ 2024-12-30T18:56:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stenoparib-allarity-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-papillary-thyroid-cancer-likelihood-of-approval/ 2024-12-30T18:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:55:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ln-145-iovance-biotherapeutics-rhabdomyosarcoma-likelihood-of-approval/ 2024-12-30T18:55:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/soquelitinib-corvus-pharmaceuticals-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-12-30T18:55:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:55:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibp-9414-infant-bacterial-therapeutics-necrotizing-enterocolitis-likelihood-of-approval/ 2024-12-30T18:55:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retifanlimab-incyte-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:55:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceb-01-cebiotex-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T18:55:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biobetter-shanghai-henlius-biotech-rectal-cancer-likelihood-of-approval/ 2024-12-30T18:55:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-bladder-cancer-likelihood-of-approval/ 2024-12-30T18:55:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gt-0002x-gene-therapy-research-institution-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T18:55:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-2-replimune-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-12-30T18:55:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adpa-2afp-adaptimmune-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:55:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mw-151-immunochem-therapeutics-cognitive-disorders-likelihood-of-approval/ 2024-12-30T18:55:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-207-angiocrine-bioscience-anal-fissure-likelihood-of-approval/ 2024-12-30T18:55:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:55:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-30T18:55:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-30T18:54:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mosedipimod-enzychem-lifesciences-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T18:54:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-lung-adenocarcinoma-likelihood-of-approval/ 2024-12-30T18:54:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adpa-2afp-adaptimmune-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-12-30T18:54:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T18:54:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asn-008-formation-bio-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-30T18:54:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cordin-gamida-cell-aplastic-anemia-likelihood-of-approval/ 2024-12-30T18:54:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T18:54:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:54:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-30T18:54:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-64315-les-laboratoires-servier-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:54:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T18:54:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mazdutide-eli-lilly-and-co-polycystic-ovarian-syndrome-likelihood-of-approval/ 2024-12-30T18:54:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cin-103-cinphloro-pharma-irritable-bowel-syndrome-likelihood-of-approval/ 2024-12-30T18:54:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:54:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mosunetuzumab-genentech-usa-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-12-30T18:54:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ruvembri-biophytis-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T18:54:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-cervical-cancer-likelihood-of-approval/ 2024-12-30T18:54:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efzofitimod-atyr-pharma-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T18:53:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-leiomyosarcoma-likelihood-of-approval/ 2024-12-30T18:53:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glm-101-glycomine-congenital-disorder-of-glycosylation-type-i-a-likelihood-of-approval/ 2024-12-30T18:53:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zegocractin-calcimedica-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T18:53:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilparencel-prokidney-unspecified-genito-urinary-disorders-likelihood-of-approval/ 2024-12-30T18:53:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olverembatinib-ascentage-pharma-group-international-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T18:53:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metopimazine-mesylate-neurogastrx-emesis-vomiting-likelihood-of-approval/ 2024-12-30T18:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-autologous-mesenchymal-stem-cells-bioinova-cartilage-degeneration-likelihood-of-approval/ 2024-12-30T18:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/latanoprost-sr-peregrine-ophthalmic-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2024-12-30T18:53:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metopimazine-mesylate-neurogastrx-nausea-likelihood-of-approval/ 2024-12-30T18:53:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-30T18:53:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-rectal-cancer-likelihood-of-approval/ 2024-12-30T18:53:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selicrelumab-f-hoffmann-la-roche-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T18:53:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lacripep-tearsolutions-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-12-30T18:53:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-12-30T18:53:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-r-pharm-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:53:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dilanubicel-deverra-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T18:52:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezabenlimab-boehringer-ingelheim-international-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-30T18:52:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chlorogenic-acid-sichuan-j-z-bio-chemical-science-and-technology-development-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:52:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-r-pharm-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:52:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-oncology-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:52:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifaquizinone-tennor-therapeutics-skin-and-skin-structure-infections-sssi-likelihood-of-approval/ 2024-12-30T18:52:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4002-gc-cell-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-12-30T18:52:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/creavax-pc-jw-creagene-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T18:52:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-30T18:52:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:52:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:52:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:52:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolebrutinib-sanofi-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2024-12-30T18:52:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T18:52:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-laryngeal-cancer-likelihood-of-approval/ 2024-12-30T18:52:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T18:52:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceralasertib-astrazeneca-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T18:52:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d2c7-it-istari-oncology-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:52:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-gliosarcoma-likelihood-of-approval/ 2024-12-30T18:51:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T18:51:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-rectal-cancer-likelihood-of-approval/ 2024-12-30T18:51:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adpa-2afp-adaptimmune-therapeutics-malignant-neoplasms-likelihood-of-approval/ 2024-12-30T18:51:46+00:00 daily 0.2